Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Pipeline COVID-19 Vaccines Not Affected by ‘G-Strain’ Mutation

by Global Biodefense Staff
October 8, 2020
Pipeline COVID-19 Vaccines Not Affected by ‘G-Strain’ Mutation

Credit: NIAID

In a new study, researchers from the Dangerous Pathogens Team at CSIRO conclude vaccines currently under development for COVID-19 should not be affected by recent mutations in the virus.

Most vaccines under development worldwide have been modelled on the original ‘D-strain’ of the virus, which were more common amongst sequences published early in the pandemic.

Since then, the virus has evolved to the globally dominant ‘G-strain’, which now accounts for about 85 per cent of published SARS-CoV-2 genomes.

Professor Seshadri Vasan, honorary chair in Health Sciences at the University of York, head of Dangerous Pathogens Team at CSIRO. Credit: University of York

There had been fears the G-strain, within the main protein on the surface of the virus, would negatively impact on vaccines under development. But the research by Australia’s national science agency the Commonwealth Scientific and Industrial Research Organisation (CSIRO), found no evidence the change would adversely impact the efficacy of vaccine candidates.

The study tested blood samples from ferrets given a candidate vaccine against virus strains that either possessed or lacked this mutation (known as ‘D614G’).

Professor Seshadri Vasan, who holds an honorary chair in Health Sciences at the University of York, is leading the Dangerous Pathogens Team at CSIRO and is senior author of the paper.

Professor Vasan said: “This is good news for the hundreds of vaccines in development around the world, with the majority targeting the spike protein as this binds to the ACE2 receptors in our lungs and airways, which are the entry point to infect cells.

“Despite this D614G mutation to the spike protein, we confirmed through experiments and modelling that vaccine candidates are still effective.

“We’ve also found the G-strain is unlikely to require frequent ‘vaccine matching’ where new vaccines need to be developed seasonally to combat the virus strains in circulation, as is the case with influenza.”

CSIRO Chief Executive Dr. Larry Marshall said the research was critically important in the race to develop a vaccine.

“This brings the world one step closer to a safe and effective vaccine to protect people and save lives,” noted Marshall. “Research like this, at speed, is only possible through collaboration with partners in Australia and globally. We are tackling these challenges head on and delivering solutions through world-leading science.”

Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein.

Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein. npj Vaccines, 8 October 2020.

Tags: Clinical TrialsCOVID CountermeasuresCOVID-19Drug DevelopmentEditor PickGenomicsSARS-CoV-2Vaccines

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC